Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, reduced the risk of cardiovascular death or heart failure events in 4,744 patients with chronic heart failure with reduced ejection fraction.
This is a preview of subscription content, access via your institution
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
White, J. R. Clin. Diabetes 28, 5–10 (2010).
Greene, S. J. et al. J Am Coll Cardiol 71, 1379–1390 (2018).
Zelniker, T. A. et al. Lancet 393, 31–39 (2019).
Neuen, B. L. et al. Lancet Diabetes Endocrinol. https://doi.org/10.1016/S2213-8587(19)30256-6 (2019).
Verma, S. & McMurray, J. J. V. Circulation 139, 2537–2541 (2019).
McMurray, J. J. V. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1911303 (2019).
Inzucchi, S. E. et al. Diabetes Care 41, 356–363 (2018).
Vijayakumar, S., Vaduganathan, M. & Butler, J. Circulation 137, 1060–1073 (2018).
Greene, S. J. et al. J. Am. Coll. Cardiol. 72, 351–366 (2018).
Greene, S. J. et al. J. Am. Coll. Cardiol. 73, 2365–2383 (2019).
M.V. is supported by the KL2/Catalyst Medical Research Investigator Training award from Harvard Catalyst (NIH/NCATS Award UL 1TR002541), serves on advisory boards for Amgen, AstraZeneca, Baxter Healthcare, Bayer AG, Boehringer Ingelheim and Relypsa, and participates on clinical endpoint committees for studies sponsored by Novartis and the NIH. J.B. has served as a consultant to Abbott, Amgen, Array, Applied Therapeutics, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, CVRx, G3 Pharma, Gilead, Impulse Dynamics, Innolife, Janssen, LivaNova, Luitpold, Medtronic, Merck, Novartis, NovoNordisk, Relypsa, Roche, Sanofi, V-Wave Limited and Vifor.
Rights and permissions
About this article
Cite this article
Vaduganathan, M., Butler, J. SGLT-2 inhibitors in heart failure: a new therapeutic avenue. Nat Med 25, 1653–1654 (2019). https://doi.org/10.1038/s41591-019-0647-4